TNYA Stock Price, Tenaya Therapeutics, . Quote, Chart

Market Summary

USD4.38-0.07

Market Closed

-1.57%

TNYA Stock Price

View Fullscreen

TNYA RSI Chart

TNYA Valuation

Market Cap

349.4M

Price/Earnings (Trailing)

-2.82

EV/EBITDA

-2.63

Price/Free Cashflow

-3.38

MarketCap/EBT

-2.82

TNYA Price/Earnings (Trailing)

TNYA Profitability

Return on Equity

-89.02%

Return on Assets

-72.78%

Free Cashflow Yield

-29.57%

TNYA Fundamentals

TNYA Earnings

Earnings (TTM)

-124.1M

Earnings Growth (Yr)

10.68%

Earnings Growth (Qtr)

-2.8%

Breaking Down TNYA Revenue

Last 7 days

-0.2%

Last 30 days

-5.7%

Last 90 days

1.6%

Trailing 12 Months

-23.4%

How does TNYA drawdown profile look like?

TNYA Financial Health

Current Ratio

4.91

TNYA Investor Care

Shares Dilution (1Y)

64.62%

Diluted EPS (TTM)

-1.68

Tracking the Latest Insider Buys and Sells of Tenaya Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	hoey timothy	sold	-23,101	7.0003	-3,300	chief scientific officer
Feb 23, 2024	tingley whittemore	acquired	-	-	35,000	chief medical officer
Feb 23, 2024	ali faraz	acquired	-	-	85,000	chief executive officer
Feb 23, 2024	hoey timothy	acquired	-	-	12,500	chief scientific officer
Feb 23, 2024	patterson leone d	acquired	-	-	35,000	chief fin. and bus. officer
Feb 20, 2024	hoey timothy	sold	-35,046	5.33506	-6,569	chief scientific officer
Feb 16, 2024	patterson leone d	sold	-30,477	5.86	-5,201	chief fin. and bus. officer
Feb 16, 2024	hoey timothy	sold	-27,430	5.86	-4,681	chief scientific officer
Feb 16, 2024	ali faraz	sold	-37,257	5.86	-6,358	chief executive officer
Feb 16, 2024	tingley whittemore	sold	-38,090	5.86	-6,500	chief medical officer

Which funds bought or sold TNYA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-72.1	-6,000	5,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-64,127	-	-%
Apr 19, 2024	DENALI ADVISORS LLC	unchanged	-	86,167	226,459	0.07%
Apr 17, 2024	ATTICUS WEALTH MANAGEMENT, LLC	reduced	-18.48	70,948	295,558	0.10%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 26, 2024	HighPoint Advisor Group LLC	new	-	342,000	342,000	0.02%
Mar 11, 2024	VANGUARD GROUP INC	added	13.45	2,440,540	7,968,600	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	25.41	179,752	482,662	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	1.09	16,565	74,815	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	1.55	3,313,000	14,725,000	-%

Are Funds Buying or Selling TNYA?

Are funds buying TNYA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNYA

No. of Funds

Unveiling Tenaya Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	6.7%	4,544,543	SC 13G/A
Feb 14, 2024	column group iii, lp	5.7%	4,414,720	SC 13D/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	6,948,236	SC 13G/A
Jan 31, 2024	blackrock inc.	5.6%	3,786,824	SC 13G
Feb 21, 2023	column group iii, lp	6.9%	4,414,720	SC 13D/A
Feb 14, 2023	ra capital management, l.p.	9.99%	6,428,483	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	6.7%	4,472,202	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Dec 07, 2022	casdin capital, llc	9.9%	6,427,200	SC 13D/A

Recent SEC filings of Tenaya Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	ARS	ARS
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	DEFA14A	DEFA14A
Mar 18, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 05, 2024	144	Notice of Insider Sale Intent
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to Tenaya Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Tenaya Therapeutics, Inc. News

Latest updates

Tenaya Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-11.8%	171	193	221	245	279	226	256	281	314	332	157	148
Current Assets	-12.0%	112	127	139	155	194	157	186	214	255	285	113	130
Cash Equivalents	-44.4%	46.00	82.00	76.00	73.00	95.00	34.00	31.00	26.00	38.00	117	112	129
Net PPE	-4.1%	43.00	45.00	47.00	49.00	51.00	52.00	53.00	49.00	43.00	31.00	25.00	17.00
Liabilities	9.0%	31.00	29.00	31.00	30.00	36.00	30.00	32.00	32.00	36.00	28.00	25.00	9.00
Current Liabilities	17.3%	23.00	19.00	21.00	19.00	24.00	18.00	19.00	19.00	22.00	14.00	10.00	5.00
Shareholder's Equity	-15.4%	139	165	190	215	243	196	224	249	279	304	-	-
Retained Earnings	-8.0%	-403	-373	-344	-310	-279	-245	-215	-186	-155	-129	-111	-82.81
Additional Paid-In Capital	0.8%	543	538	534	526	523	443	440	436	434	433	3.00	2.00
Shares Outstanding	-7.1%	68.00	74.00	73.00	73.00	67.00	41.00	41.00	41.00	41.00	27.00	-	1.00
Float	-	-	-	272	-	-	-	156	-	528	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	7.3%	-21,924	-23,638	-26,220	-30,290	-22,682	-27,556	-25,430	-28,756	-16,347	-16,657	-12,019	-15,789	-	-	-
Share Based Compensation	-1.6%	3,949	4,015	3,831	3,514	3,187	3,174	3,012	2,094	1,048	968	502	432	-	-	-
Cashflow From Investing	-148.9%	-14,919	30,488	25,085	8,061	5,974	31,034	30,210	16,434	-62,580	-168,425	-3,236	-4,323	-	-	-
Cashflow From Financing	-	371	-	4,179	-501	77,486	6.00	260	15.00	-21.00	190,274	-1,298	20,015	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	3.00	-	-	-	-	-

TNYA Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 98,038	$ 94,537
General and administrative	33,155	31,084
Total operating expenses	131,193	125,621
Loss from operations	(131,193)	(125,621)
Other income, net:
Interest income	7,056	1,954
Other income, net	53	2
Total other income, net	7,109	1,956
Net loss before income tax expense	(124,084)	(123,665)
Net loss	(124,084)	(123,665)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable securities	272	(237)
Comprehensive loss	$ (123,812)	$ (123,902)
Net loss per share, basic	$ (1.68)	$ (2.76)
Net loss per share, diluted	$ (1.68)	$ (2.76)
Weighted-average shares used in computing net loss per share, basic	73,786,126	44,823,597
Weighted-average shares used in computing net loss per share, diluted	73,786,126	44,823,597

TNYA Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 45,681	$ 95,272
Short-term investments in marketable securities	58,961	91,255
Prepaid expenses and other current assets	6,940	7,227
Total current assets	111,582	193,754
Property and equipment, net	43,277	51,032
Operating lease right-of-use assets	9,979	11,663
Long-term investments in marketable securities		17,703
Other noncurrent assets	5,677	4,793
Total assets	170,515	278,945
Current liabilities:
Accounts payable	5,630	9,578
Accrued and other current liabilities	12,784	10,664
Operating lease liabilities, current	4,319	4,006
Total current liabilities	22,733	24,248
Operating lease liabilities, noncurrent	8,105	11,093
Other noncurrent liabilities	253	228
Total liabilities	31,091	35,569
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding as of December 31, 2023 and 2022
Common stock, $0.0001 par value; 1,000,000,000 shares authorized as of December 31, 2023 and 2022; 68,330,342 and 66,857,113 shares issued and outstanding as of December 31, 2023 and 2022	7	7
Additional paid-in capital	542,805	522,945
Accumulated other comprehensive loss	(106)	(378)
Accumulated deficit	(403,282)	(279,198)
Total stockholders' equity	139,424	243,376
Total liabilities and stockholders' equity	$ 170,515	$ 278,945

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

CEO	Mr. Faraz Ali M.B.A.
WEBSITE	tenayatherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	141

Tenaya Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Tenaya Therapeutics, Inc.? What does TNYA stand for in stocks?

TNYA is the stock ticker symbol of Tenaya Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tenaya Therapeutics, Inc. (TNYA)?

As of Tue Apr 23 2024, market cap of Tenaya Therapeutics, Inc. is 349.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNYA stock?

You can check TNYA's fair value in chart for subscribers.

What is the fair value of TNYA stock?

You can check TNYA's fair value in chart for subscribers. The fair value of Tenaya Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tenaya Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNYA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tenaya Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TNYA is over valued or under valued. Whether Tenaya Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Tenaya Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNYA.